BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-64@pharmaconomics
DTSTAMP:20260707T034116Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:RHHBY Phase 3 — Afimkibart
DESCRIPTION:Phase 3 trial results for Afimkibart in Moderately to Severely Active Ulcerative Colitis are due Jan 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06588855\n\nTrack it: https://www.pharmaconomics.com/e/64
URL:https://www.pharmaconomics.com/e/64
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RHHBY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR